Abstracts tagged "Myopathies"

Abstract Number: 0281 • ACR Convergence 2025
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Anja Srpcic¹, Manca Ogric¹, Sasa Cucnik¹, Sergej Pirkmajer², Katja Lakota¹ and Katja Perdan Pirkmajer¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
Abstract Number: 2068 • ACR Convergence 2025
Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
Michael George¹, Thomas Riley¹, Ellen Romich², Emily Holladay³, Tim Beukelman⁴, Shanette Daigle⁵, Amy Mudano⁵, Fenglong Xie⁶, Xiang Guo⁷, Nicole Kulisek⁸, Arne Yndestad⁹, Ashraf Chaudhary⁸ and Jeffrey Curtis¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Pfizer, Inc, New York, NY, ⁸Pfizer, Inc, Collegeville, PA, ⁹Pfizer Inc, Oslo, Norway, Oslo, Norway, ¹⁰Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Studies of idiopathic inflammatory myopathies (IIM) are often based on the analysis of single cohorts at academic centers. We aimed to identify potential gaps…
Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Darya S. Jalaledin¹, Aidan pye², Angela Chang², Navid Saleh², Saud AlHajeri³, Beatrice Daviault⁴, Arusa Shah⁵, Sabrina Hoa⁶, Océane Landon-Cardinal⁷, Alec Yu², Robert Levy⁸, Jennifer Wilson⁹, Charles Poirier⁴, James Choi², John Yee², Hyein Kim² and Kun Huang¹⁰, ¹Université de Montréal, Saint-Lambert, QC, Canada, ²University of British Columbia, VANCOUVER, BC, Canada, ³University of British Columbia, Vancouver, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹UBC, Vancouver, BC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…
Abstract Number: 2067 • ACR Convergence 2025
Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Ilke Coskun Benlidayi¹, Meghna Lama², Oladipo Kunle Afolayan², Meera Shah³, Manali Sarkar⁴, Tamar Rubinstein⁵, Aleksandra Opinc-Rosiak⁶, Rada Miskovic⁷, Marcin Milchert⁸, Dimitri Luz Felipe da Silva⁹, Samuel Katsuyuki Shinjo¹⁰, Elena Nikiphorou¹¹, Ioannis Parodis¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Cukurova University, Adana, Turkey, ²The University of Texas Health Science Centre at Houston School of Public Health: Houston, Texas, Houston, ³Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ⁴Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁵Albert Einstein College of Medicine, White Plains, NY, ⁶Medical University of Lodz, Zeromskiego ¹¹³, ⁹⁰-⁵⁴⁹ Lodz, Poland., Lodz, Poland, ⁷University of Belgrade; Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Belgrade, Serbia, ⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁹University Santo Amaro, São Paulo, Brazil, Sao Paulo, Brazil, ¹⁰Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹¹King's College London, London, United Kingdom, ¹²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This…
Abstract Number: 1196 • ACR Convergence 2025
Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies
Anuya Natu¹, Haley Zimmerman², Kristin Wipfler³, Kaleb Michaud⁴, Yvonne Lee⁵ and Didem Saygin², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Northwestern University, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…
Abstract Number: 2066 • ACR Convergence 2025
Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Meera Shah¹, Emilia Naseva², Tsvetelina Velikova³, Tamar Rubinstein⁴, Manali Sarkar⁵, Lavanya Mangla⁶, Oliver Distler⁷, Ingrid de Groot⁸, Lisa Christ⁹, Carlo Vinicio Caballero Uribe¹⁰, Ai Lyn Tan¹¹, Abraham Edgar Gracia Ramos¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ²Faculty of Public Health, Medical University of Sofia, ¹⁵ Acad. Ivan Evstratiev Geshov, ¹⁶⁰⁶ Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ³Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ⁴Albert Einstein College of Medicine, White Plains, NY, ⁵Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁶Maulana Azad Medical College, ²-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁸The Myositis Association, Rotterdam, Netherlands, ⁹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ¹⁰Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ¹¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ¹²Department of Internal Medicine, General Hospital, National Medical Center “La Raza”, Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. ⁰²⁹⁹⁰ Mexico City, Mexico., Mexico City, Mexico, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Traditional clinical measures are well established in idiopathic inflammatory myopathies (IIM), yet exploration of subjective well-being (SWB) remains limited. SWB assessment facilitates holistic patient…
Abstract Number: 1193 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Angela Chang¹, Navid Saleh¹, Alec Yu¹, Darya S. Jalaledin², Sabrina Hoa³, Robert Levy⁴, Jennifer Wilson⁵, Charles Poirier⁶, John Yee¹, James Choi¹, Océane Landon-Cardinal⁷, Hyein Kim⁸ and Kun Huang⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Université de Montréal, Saint-Lambert, QC, Canada, ³University of Montreal, Brossard, QC, Canada, ⁴University of British Columbia, Deerfield, IL, ⁵UBC, Vancouver, BC, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸The University of British Columbia, Vancouver, BC, Canada, ⁹University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…
Abstract Number: 2064 • ACR Convergence 2025
Kinematics Underlying IBM-induced Dysphagia
Kevin Renz Ambrocio¹, Vaidehi Kothari¹, Rohit Aggarwal², Anna Miles³, James L. Coyle¹, Eaman Alhassan⁴, Sandra Stinnett¹, David Lacomis¹, Lea Sayce¹ and Kendrea (Focht) Garand¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ³The University of Auckland, Auckland, New Zealand, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Dysphagia remains a key contributor to mortality in IBM due to its connection with aspiration pneumonia and malnutrition (Shelly et al., 2021). Compared to…
Abstract Number: 1192 • ACR Convergence 2025
Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Sandra G Pasoto¹, Thais B Gorayeb², Ana Paula Luppino-Assad³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro¹, Leonard V Kupa⁵, Bruno S Borges⁶, Samuel K Shinjo⁷, Fernando H De Souza², Renata Miossi², Eloisa Bonfa⁸ and Clovis Artur Silva⁹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SÃO PAULO, Brazil, ⁸Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁹University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Although herpes zoster vaccination has been evaluated in immunocompromised populations, studies assessing vaccine immunogenicity and safety in idiopathic inflammatory myopathies (IIM) are restricted to…
Abstract Number: 2060 • ACR Convergence 2025
Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
Irene Peralta-García¹, Naz Haque², Dag Leonard³, Anna Glasin⁴, Silva Puksic⁵, Balsam Hanna⁶, My Axelhed⁷, Theodoros Lappas⁵, Farbicio Espinosa Ortega¹, Karin Lodin¹, NIls Eckerdal², Helene Alexanderson⁸, Elizabeth Hsia⁹, Federico Zazzetti¹⁰, Ingrid Lundberg¹¹ and Marie Holmqvist¹, ¹Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden, ²Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology Department, Linköping Hospital, LInköping, Sweden, ⁵Rheumatology Department, Örebro University Hospital, Örebro, Sweden, ⁶Rheumatology Department, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁷Rheumatology Department, Västmanlands Hospital, Västerås, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Johnson & Johnson, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Due to the rarity and heterogeneity of idiopathic inflammatory myopathies (IIM), we lack robust randomized trials to guide treatment decisions. Most of current practice…
Abstract Number: 1037 • ACR Convergence 2025
Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Zixing Liu¹, Adrianne Woods², Julie Paik², Laura Hummers², Scott Zeger¹, Ami Shah² and Ji Soo Kim³, ¹Johns Hopkins Biostatistics, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD, ³Johns Hopkins, Baltimore, MD
Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
Abstract Number: 2058 • ACR Convergence 2025
Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
valeria cantu¹, Emmanuel Dominguez-Chapa², Rebeca L. Polina-Lugo¹, Ana Cecilia Bardan Inchaustegui³, fernanda m. garcia-Carrillo⁴, Ericka S. Reyna-Hernandez⁵, Daniela A. Mejia-Rodriguez⁵, Rosa Arvizu-Rivera⁶, Jesus Alberto Cardenas-de la Garza⁷, Miguel Villarreal-Alarcón⁸ and Dionicio A. Galarza-Delgado⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁷Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁸Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare diseases that involve chronic muscle inflammation, weakness, and pain. Autoantibodies in IIM play a central role in disease…
Abstract Number: 0773 • ACR Convergence 2025
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima², Motohiro Nonaka³, Norimichi Nomura⁴, Atsubumi Ogawa¹, Yasuhiro Nohda¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Hajime Yoshifuji², Shogo Matsuda⁵, Masao Katsushima⁶, Michinori Ishitoku⁷, Yusuke Yoshida⁷, Yasuyuki Todoroki⁸, Satoshi Kubo⁹, Tomohiro Handa¹⁰, Hiromi Tomioka¹¹, Ryo Tachikawa¹², Keisuke Tomii¹², Kiminobu Tanizawa¹³, Toru Arai¹⁴, Takuya Kotani¹⁵, Motomu Hashimoto¹⁶, Shintaro Hirata⁷, Yoshiya Tanaka¹⁷, Tsuneyo Mimori¹⁸ and Akio Morinobu¹⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶Department of Clinical Immunology, Osaka Metropolitan Graduate School of Medicine, Osaka, Japan, ⁷Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁸Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Department of Advanced Medicine for Respiratory Failure and Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹¹Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, ¹³Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, ¹⁴Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Sakai, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ¹⁶Osaka Metropolitan University, Osaka, Japan, ¹⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁸Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ¹⁹Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Melanoma differentiation-associated gene 5 (MDA5) is a cytoplasmic RNA sensor and activates the innate immune response. Autoantibodies against MDA5 are associated with rapidly progressive…
Abstract Number: 2057 • ACR Convergence 2025
Clinical Associations of Anti-Ro52 Antibodies in Idiopathic Inflammatory Myopathies: A Scoping Review
Emily Sun¹, Huon Wong², Robin Sia³ and Jessica Day⁴, ¹Royal Melbourne Hospital, Melbourne, Victoria, Australia, ²University of Queensland, Brisbane, Australia, ³Royal Melbourne Hospital, Reservoir, Victoria, Australia, ⁴Walter and Eliza Hall Institute, Melbourne, Victoria, Australia
Background/Purpose: Anti-Ro52 is a myositis-associated antibody increasingly linked to disease features and outcomes in idiopathic inflammatory myopathies (IIMs). Thorough characterisation of these associations is needed…
Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Vaidehi Kothari¹, Eaman Alhassan², Kevin Renz Ambrocio¹, Bonny Rockette-Wagner³, Chester V. Oddis¹, Kendrea (Focht) Garand¹ and Rohit Aggarwal⁴, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh, PITTSBURGH, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].